Log In

Forgot Password?


Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Systemic inflammatory response syndrome deteriorates the outcomes of mechanical thrombectomy in acute stroke
Cerebrovascular Disease and Interventional Neurology
P14 - Poster Session 14 (11:45 AM-12:45 PM)
Systemic inflammatory response syndrome (SIRS) has been associated with poor outcomes after acute ischemic stroke (AIS). The primary goal of this study was to determine whether SIRS status on admission correlated with functional outcomes in AIS treated with mechanical thrombectomy (MT).
In this retrospective research, we investigated the association of the systemic inflammatory response syndrome and its impact on the outcomes of mechanical thrombectomy in acute stroke. 

Consecutive patients from September 2015 to April 2019 were retrospectively reviewed for SIRS on admission. SIRS was defined as the presence of ≥2 of the following: temperature < 36 °C or > 38 °C, heart rate > 90, respiratory rate > 20, and white blood cell count <4000/mm or > 12,000 mm.

Of 202 patients, 188 met inclusion criteria. 49 patients (26%) had evidence of SIRS. Neither basic patient demographics nor standard stroke risk factors predicted the development of SIRS. However, presentation with SIRS was correlated with higher rates of death (odds ratio [OR], 2.6; 95% confidence interval [CI], 1.2–5.5) as well as lower rates of favorable functional outcomes at discharge (OR, 0.09; 95% CI, 0.02–0.40) and 3-month follow up (OR 0.12; 95% CI 0.03–0.43). These results remained significant even after adjustment for age, sex, baseline NIHSSrecanalization status, and prior co-morbidities.

In our sample population, SIRS was associated with worse outcomes and higher rates of mortality in AIS patients treated with MT. Recognition of key risk factors can provide better prognostication and possible future therapeutic targets.

Mostafa Jafari, MD (Baylor College of Medicine)
Dr. Jafari has nothing to disclose.
Kalman Katlowitz Mr. Katlowitz has nothing to disclose.
Carlos De la Garza, MD (Baylor College of Medicine) Dr. De la Garza has nothing to disclose.
Alexander Sellers, MD (Rhode Island Hospital Brown Neurology) Dr. Sellers has nothing to disclose.
Shawn Moore, MD (Baylor College of Medicine) No disclosure on file
Hayden William Joseph Hall, DO (Baylor College of Medicine) Dr. Hall has nothing to disclose.
Aaron Desai, MD, MBBS (University of South Floor) No disclosure on file
Vikramjeet Singh No disclosure on file
Rahul Damani Rahul Damani has nothing to disclose.